The Biopsychosocial Burden of Prostate Biopsy at the Time of Its Indication, Procedure, and Pathological Report.

IF 2.3 Q3 ONCOLOGY

Prostate Cancer Pub Date : 2019-04-01 eCollection Date: 2019-01-01 DOI:10.1155/2019/2653708

Walker W Laranja, Brunno C F Sanches, Brunno R I Voris, João C C Alonso, Fabiano A Simões, Ronald F Rejowski, Leonardo O Reis

{"title":"The Biopsychosocial Burden of Prostate Biopsy at the Time of Its Indication, Procedure, and Pathological Report.","authors":"Walker W Laranja, Brunno C F Sanches, Brunno R I Voris, João C C Alonso, Fabiano A Simões, Ronald F Rejowski, Leonardo O Reis","doi":"10.1155/2019/2653708","DOIUrl":null,"url":null,"abstract":"Purpose: To explore the burden of prostate biopsy at the time of its indication, procedure, and pathological report in the prostate cancer-screening scenario that is neglected and underestimated in the literature.Methods: Prostate biopsy was offered to 47 consecutive patients with prostate-specific antigen (PSA) over 4 ng/dl or suspicious digital rectal examination (DRE) of whom 16 had undergone a biopsy. Comprehensive validated questionnaires at Time 0 (prebiopsy), Time 1 (before diagnosis, 20 days after biopsy), and Time 2 (after diagnosis, 40 days after biopsy) accessed patients' erectile (IIEF-5) and voiding (IPSS) functions, Beck scales measured anxiety (BAI), hopelessness (BHS), and depression (BDI), added to the emotional thermometers including five visual analog scales for distress, anxiety, depression, anger, and need for help. The Mann-Whitney or Friedman tests were obtained among times and studied variables.Results: Prostate biopsy did not significantly impact patients' erectile and voiding functions while a higher Beck anxiety index (BAI) was observed at Time 0 (6.89 ± 6.33) compared to Time 1 (4.83 ± 2.87), p=0.0214, and to Time 2 (4.22 ± 4.98), p=0.0178. At Time 0, patients that experienced a previous biopsy presented higher distress (3.1 ± 3.0 vs. 1.6 ± 2.3), p=0.043, and emotional suffering thermometer scores (2.3 ± 3.3 vs. 0.9 ± 2.4) compared to those undergoing the first biopsy, p=0.036. At Time 2, patients with positive biopsies compared with those with negative ones showed no significant difference in outcome scores. The sample power was >90%.Conclusions: To be considered in patients' counseling and care, the current study supports the hypothesis that the peak burden of prostate biopsy occurs at the time of its indication and might be higher for those experiencing rebiopsy, significantly impacting patients' psychosocial domains.Trial approval: This trial is registered under number NCT03783741.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2019 ","pages":"2653708"},"PeriodicalIF":2.3000,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/2653708","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2019/2653708","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Purpose: To explore the burden of prostate biopsy at the time of its indication, procedure, and pathological report in the prostate cancer-screening scenario that is neglected and underestimated in the literature.

Methods: Prostate biopsy was offered to 47 consecutive patients with prostate-specific antigen (PSA) over 4 ng/dl or suspicious digital rectal examination (DRE) of whom 16 had undergone a biopsy. Comprehensive validated questionnaires at Time 0 (prebiopsy), Time 1 (before diagnosis, 20 days after biopsy), and Time 2 (after diagnosis, 40 days after biopsy) accessed patients' erectile (IIEF-5) and voiding (IPSS) functions, Beck scales measured anxiety (BAI), hopelessness (BHS), and depression (BDI), added to the emotional thermometers including five visual analog scales for distress, anxiety, depression, anger, and need for help. The Mann-Whitney or Friedman tests were obtained among times and studied variables.

Results: Prostate biopsy did not significantly impact patients' erectile and voiding functions while a higher Beck anxiety index (BAI) was observed at Time 0 (6.89 ± 6.33) compared to Time 1 (4.83 ± 2.87), p=0.0214, and to Time 2 (4.22 ± 4.98), p=0.0178. At Time 0, patients that experienced a previous biopsy presented higher distress (3.1 ± 3.0 vs. 1.6 ± 2.3), p=0.043, and emotional suffering thermometer scores (2.3 ± 3.3 vs. 0.9 ± 2.4) compared to those undergoing the first biopsy, p=0.036. At Time 2, patients with positive biopsies compared with those with negative ones showed no significant difference in outcome scores. The sample power was >90%.

Conclusions: To be considered in patients' counseling and care, the current study supports the hypothesis that the peak burden of prostate biopsy occurs at the time of its indication and might be higher for those experiencing rebiopsy, significantly impacting patients' psychosocial domains.

Trial approval: This trial is registered under number NCT03783741.

Abstract Image

查看原文本刊更多论文

前列腺活检在其适应症、程序和病理报告时的生物心理社会负担。

目的:探讨前列腺活检在其适应症，程序和病理报告时的负担，在前列腺癌筛查场景中被忽视和低估的文献。方法:对47例前列腺特异性抗原(PSA)高于4 ng/dl或可疑的直肠指检(DRE)患者进行前列腺活检，其中16例进行了活检。在时间0(活检前)、时间1(诊断前、活检后20天)和时间2(诊断后、活检后40天)对患者的勃起(IIEF-5)和排尿(IPSS)功能进行了全面的有效问卷调查，贝克量表测量了焦虑(BAI)、绝望(BHS)和抑郁(BDI)，并添加了情绪温度计，包括5种视觉模拟量表，包括痛苦、焦虑、抑郁、愤怒和需要帮助。曼-惠特尼或弗里德曼检验是在不同的时间和研究变量之间获得的。结果:前列腺活检对患者的勃起和排尿功能无显著影响，但Beck焦虑指数(BAI)在时间0(6.89±6.33)高于时间1(4.83±2.87)，p=0.0214，时间2(4.22±4.98)，p=0.0178。在时间0时，与第一次活检的患者相比，经历过既往活检的患者表现出更高的痛苦(3.1±3.0比1.6±2.3)，p=0.043，情绪痛苦温度计评分(2.3±3.3比0.9±2.4)，p=0.036。时间2时，活检阳性患者与阴性患者的预后评分无显著差异。样品功率>90%。结论:考虑到患者的咨询和护理，目前的研究支持这样的假设，即前列腺活检的高峰负担发生在其适应症的时候，对于那些经历了再次活检的人来说可能更高，显著影响患者的心理社会领域。试验审批:本试验注册号为NCT03783741。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate Cancer ONCOLOGY-

CiteScore

2.70

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Prostate Cancer is a peer-reviewed, Open Access journal that provides a multidisciplinary platform for scientists, surgeons, oncologists and clinicians working on prostate cancer. The journal publishes original research articles, review articles, and clinical studies related to the diagnosis, surgery, radiotherapy, drug discovery and medical management of the disease.